Last Updated: 16 Sep 2024
Executive Summary
Standard Biotools Inc. (LAB) is a life sciences company that manufactures and sells laboratory analytical instruments. The company's latest stock price is $2.06, and it has a market capitalization of $764.58 million. LAB is currently unprofitable, with an EBITDA of -$104.31 million and a net loss of -$87.93 million for the trailing twelve months. However, the company is growing rapidly, with revenue increasing by 14.2% year-over-year. Analysts are bullish on LAB, with a consensus target price of $3.17 and a majority of analysts rating the stock a "buy."
Company Overview
Standard Biotools Inc. was founded in 2001 and is headquartered in South San Francisco, California. The company designs, develops, manufactures, and markets a range of laboratory analytical instruments, including PCR instruments, real-time PCR instruments, and digital PCR instruments. LAB's products are used in a variety of applications, including genetic testing, molecular diagnostics, and research.
Fundamental Analysis
LAB is currently unprofitable, but the company is growing rapidly. Revenue increased by 14.2% year-over-year to $136.3 million for the trailing twelve months. The company's gross margin is -1.06%, and its operating margin is -29.4%. LAB has a book value of $1.23 per share and a trailing twelve months EPS of -$0.88.
LAB's financial performance is expected to improve in the coming years. The company is investing heavily in research and development, and it is expanding its sales force. Analysts expect LAB to become profitable in 2025.
Technical Analysis
LAB's stock price has been trading in a range between $1.21 and $3.05 over the past 52 weeks. The stock is currently trading near the bottom of its range. The 50-day moving average is $1.967, and the 200-day moving average is $2.284. The relative strength index (RSI) is 34.3, which indicates that the stock is oversold.
Short Term Outlook
LAB's stock price is expected to remain range-bound in the short term. The company is facing headwinds from the COVID-19 pandemic, and it is unclear when the company will become profitable. However, LAB's long-term prospects are bright, and the stock is a good value at current levels.
Long Term Outlook
LAB is a well-positioned company in a growing market. The company's products are used in a variety of applications, and LAB has a strong track record of innovation. Analysts expect LAB to become profitable in 2025, and the company's stock price is expected to appreciate significantly over the long term.
Analyst Recommendations
The majority of analysts rate LAB a "buy." The consensus target price is $3.17, which represents a potential upside of 54.4% from the current price.
